ASN004, a 5T4-targeting scFv-Fc antibody-drug conjugate with high drug-to-antibody ratio, induces complete and durable tumor regressions in preclinical models

2021 ◽  
pp. molcanther.0565.2020
Author(s):  
Roger A Smith ◽  
David J Zammit ◽  
Nitin K Damle ◽  
Helen Usansky ◽  
Sanjeeva P Reddy ◽  
...  
Keyword(s):  
Preclinical Models ◽  
Antibody Drug Conjugate ◽  
High Drug ◽  
Drug Conjugate ◽  
Antibody Ratio ◽  
Antibody Drug

scholarly journals Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

2018 ◽  
Vol 17 (10) ◽  
pp. 2176-2186 ◽  
Author(s):  
Song Cho ◽  
Francesca Zammarchi ◽  
David G. Williams ◽  
Carin E.G. Havenith ◽  
Noel R. Monks ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Antitumor Activity ◽  
Preclinical Models ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug

SYD985, a novel HER2-targeting antibody-drug conjugate in preclinical models for USC, both in vitro and in vivo.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e16527-e16527 ◽  
Author(s):  
Jonathan Black ◽  
Salvatore Lopez ◽  
Emiliano Cocco ◽  
Stefania Bellone ◽  
Elena Bonazzoli ◽  
...  
Keyword(s):  
Preclinical Models ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document